Scandinavian Biopharma is focused on developing innovative vaccine solutions, particularly targeting enterotoxigenic Escherichia coli (ETEC), which is a leading cause of travel-related diarrhea. Their flagship product, the ETVAX® vaccine, is designed to provide protection against ETEC infections, with a specific pediatric formulation tailored for children under five years old in low- and middle-income countries. This vaccine is presented as a self-contained solution that can be administered easily, while the adult formulation involves mixing a carbonate buffer with the vaccine component to create an oral suspension. The company has conducted multiple clinical trials across various countries, yielding promising results that highlight the vaccine's potential to significantly improve global health outcomes by preventing severe diarrhea and its associated complications.

The ETVAX® vaccine is a multivalent oral vaccine that incorporates four inactivated strains of ETEC, along with a hybrid protein and a mucosal adjuvant, which work together to prevent bacterial adhesion and neutralize toxins produced by the bacteria. Scandinavian Biopharma's commitment to vaccine development is further underscored by their collaborations with notable organizations such as PATH and the EU Research and Innovation program, Horizon2020. The vaccine candidate has demonstrated a strong safety profile and high immunogenicity in trials, positioning it as a leading candidate in the global effort to combat ETEC-related diseases. The potential impact of this vaccine extends beyond individual health, as it aims to alleviate the burden of diarrhea in endemic regions and contribute to the fight against antimicrobial resistance.

Sweden

We are a research-based specialty biopharma company determined to give people all over the world a longer and better life. We are developing the first vaccine for protection against diarrhoea caused by ETEC in both travellers and endemic populations. We distribute a wide range of specialty biopharma products with focus on vaccines and immunoglobulins.

Scandinavian Biopharma

Company Details